Nov. 18, 2026 -- Providence Therapeutics, Inc., a clinical-stage biotechnology company specializing in messenger RNA (mRNA) vaccines, today announced that enrolment has started for the PaedNEO-VAX clinical trial, a world-first study evaluating personalized mRNA cancer vaccines for children and young adults with aggressive and treatment-resistant brain tumors.
Providence Therapeutics' CEO, Brad Sorenson, commented, "The PaedNEO-VAX marks a significant milestone for Providence's PTX-108 personali